• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较研究α-1a 阻滞剂(坦索罗辛)与雌激素在治疗围绝经期女性下尿路症状中的作用。

A comparative study of alpha-1a blockers (tamsulosin) versus estrogens in the treatment of lower urinary tract symptoms in perimenopausal females.

机构信息

Department of Urology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.

出版信息

Indian J Pharmacol. 2020 Jan-Feb;52(1):6-9. doi: 10.4103/ijp.IJP_545_18. Epub 2020 Mar 11.

DOI:10.4103/ijp.IJP_545_18
PMID:32201440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7074429/
Abstract

OBJECTIVE

Lower urinary tract symptoms (LUTS) in perimenopausal females are very common. It can be treated with alpha-blockers or application of topical oestrogen. The purpose of this study is to compare the efficacy of alpha-blockers versus topical estrogen in the treatment of LUTS in perimenopausal females.

MATERIALS AND METHODS

All perimenopausal females between the age group of 45 and 60 years who present with the symptom of voiding LUTS were divided into two groups. Acute urinary retention patients were excluded from the study. The first group was given alpha-blocker (tamsulosin) and other group was given topical estrogen application (0.5%-1%) in the periurethral region. Patients were followed up clinically by voiding components of the International Prostate Symptom Score and objectively by uroflowmetry and postvoid residual (PVR) urine estimation (ultrasonography).

RESULTS

Alpha-blocker group had 40 females and topical estrogen group had 40 females. During the 6-week period, 8 patients of the first group and 6 patients of the estrogen group discontinued the treatment. In the first group, pretreatment mean Qmax (maximum flow rate) of patients was 7.2 ml/s and posttreatment Qmax was 18.4. In the second group, the values were 7.4 ml/s and 10.2, respectively. This difference was statistically significant ( < 0.0001). In the first group, pretreatment PVR urine was significant, which became insignificant after the treatment, whereas in the second group, PVR was significant posttreatment also.

CONCLUSION

Alpha-1a blockers should be used as the first-line medical management in perimenopausal females with symptoms of LUTS, as they have a clear advantage over topical estrogens.

摘要

目的

围绝经期女性下尿路症状(LUTS)非常常见。可采用α受体阻滞剂或局部雌激素治疗。本研究旨在比较α受体阻滞剂与局部雌激素治疗围绝经期女性 LUTS 的疗效。

材料与方法

所有年龄在 45 至 60 岁之间出现排尿 LUTS 症状的围绝经期女性均分为两组。排除急性尿潴留患者。第一组给予α受体阻滞剂(坦索罗辛),另一组给予尿道周围局部雌激素应用(0.5%-1%)。通过国际前列腺症状评分的排尿成分以及尿流率和剩余尿量(PVR)的客观测量对患者进行临床随访(超声)。

结果

α受体阻滞剂组有 40 名女性,局部雌激素组有 40 名女性。在 6 周的治疗期间,第一组有 8 名患者和雌激素组有 6 名患者停止治疗。在第一组中,治疗前患者的平均最大尿流率(Qmax)为 7.2ml/s,治疗后 Qmax 为 18.4ml/s。在第二组中,相应的值分别为 7.4ml/s 和 10.2ml/s。这种差异具有统计学意义(<0.0001)。在第一组中,治疗前 PVR 尿液明显,治疗后不再明显,而在第二组中,治疗后 PVR 仍然明显。

结论

对于有 LUTS 症状的围绝经期女性,α-1a 受体阻滞剂应作为一线医学治疗方法,因为其具有明显优于局部雌激素的优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f83/7074429/a3caf7462982/IJPharm-52-6-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f83/7074429/8636246ae737/IJPharm-52-6-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f83/7074429/b849828fa2d6/IJPharm-52-6-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f83/7074429/a3caf7462982/IJPharm-52-6-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f83/7074429/8636246ae737/IJPharm-52-6-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f83/7074429/b849828fa2d6/IJPharm-52-6-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f83/7074429/a3caf7462982/IJPharm-52-6-g003.jpg

相似文献

1
A comparative study of alpha-1a blockers (tamsulosin) versus estrogens in the treatment of lower urinary tract symptoms in perimenopausal females.比较研究α-1a 阻滞剂(坦索罗辛)与雌激素在治疗围绝经期女性下尿路症状中的作用。
Indian J Pharmacol. 2020 Jan-Feb;52(1):6-9. doi: 10.4103/ijp.IJP_545_18. Epub 2020 Mar 11.
2
Response to "A comparative study of alpha-1a blockers (tamsulosin) versus estrogens in the treatment of lower urinary tract symptoms in perimenopausal females".对“α-1a受体阻滞剂(坦索罗辛)与雌激素治疗围绝经期女性下尿路症状的比较研究”的回应
Indian J Pharmacol. 2020 Nov-Dec;52(6):524-525. doi: 10.4103/ijp.IJP_439_20.
3
Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial.坦索罗辛和安慰剂与坦索罗辛和他达拉非治疗男性下尿路症状的比较:一项双盲、随机对照试验。
BJU Int. 2020 May;125(5):718-724. doi: 10.1111/bju.15027. Epub 2020 Feb 27.
4
A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.一项比较随机前瞻性研究,旨在评估坦索罗辛和他达拉非联合与坦索罗辛或他达拉非单药治疗良性前列腺增生所致下尿路症状的疗效和安全性。
J Sex Med. 2014 Jan;11(1):187-96. doi: 10.1111/jsm.12357. Epub 2013 Oct 25.
5
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.索利那新与坦索罗辛口服控释系统单片复方制剂治疗男性储尿和排尿下尿路症状的长期安全性和疗效:NEPTUNE 研究和 NEPTUNE II 开放性扩展研究结果。
Eur Urol. 2015 Feb;67(2):262-70. doi: 10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.
6
The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.口服坦索罗辛控释系统(OCAS)治疗良性前列腺增生症相关膀胱出口梗阻所致下尿路症状的疗效和安全性:一项开放性初步研究。
Int Braz J Urol. 2011 Jul-Aug;37(4):468-76. doi: 10.1590/s1677-55382011000400005.
7
Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials.他达拉非与坦索罗辛治疗前列腺增生症下尿路症状的疗效比较:一项随机对照试验的荟萃分析。
Med Sci Monit. 2020 Apr 24;26:e923179. doi: 10.12659/MSM.923179.
8
Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.与单独使用坦索罗辛相比,坦索罗辛与曲司氯铵联合治疗在前列腺癌种子近距离治疗后是否能改善下尿路症状?一项前瞻性、随机、对照试验。
Strahlenther Onkol. 2017 Sep;193(9):714-721. doi: 10.1007/s00066-017-1162-5. Epub 2017 Jun 13.
9
Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.坦索罗辛缓解晚期前列腺癌患者下尿路症状的临床评估。
Int Urol Nephrol. 2017 Jul;49(7):1111-1117. doi: 10.1007/s11255-017-1591-1. Epub 2017 Apr 13.
10
Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.他达拉非与坦索罗辛治疗良性前列腺增生症(BPH)所致下尿路症状(LUTS)的疗效和安全性:开放标签随机对照研究。
Int J Clin Pract. 2020 Aug;74(8):e13530. doi: 10.1111/ijcp.13530. Epub 2020 Jun 15.

引用本文的文献

1
Effects of aerobics training on anxiety, depression and sleep quality in perimenopausal women.有氧运动训练对围绝经期女性焦虑、抑郁及睡眠质量的影响。
Front Psychiatry. 2022 Nov 24;13:1025682. doi: 10.3389/fpsyt.2022.1025682. eCollection 2022.
2
Response to "A comparative study of alpha-1a blockers (tamsulosin) versus estrogens in the treatment of lower urinary tract symptoms in perimenopausal females".对“α-1a受体阻滞剂(坦索罗辛)与雌激素治疗围绝经期女性下尿路症状的比较研究”的回应
Indian J Pharmacol. 2020 Nov-Dec;52(6):524-525. doi: 10.4103/ijp.IJP_439_20.

本文引用的文献

1
Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study.坦索罗辛治疗女性非神经源性排尿功能障碍的疗效和安全性:一项 8 周前瞻性研究。
J Korean Med Sci. 2010 Jan;25(1):117-22. doi: 10.3346/jkms.2010.25.1.117. Epub 2009 Dec 26.
2
The effect of terazosin on functional bladder outlet obstruction in women: a pilot study.特拉唑嗪对女性功能性膀胱出口梗阻的影响:一项初步研究。
J Urol. 2006 Oct;176(4 Pt 1):1487-92. doi: 10.1016/j.juro.2006.06.009.
3
Relationship between Escherichia coli strains causing urinary tract infection in women and the dominant faecal flora of the same hosts.
引起女性尿路感染的大肠杆菌菌株与同一宿主的优势粪便菌群之间的关系。
Epidemiol Infect. 2006 Oct;134(5):1015-23. doi: 10.1017/S0950268806005917. Epub 2006 Jan 26.
4
Use of alpha1-blockers in female functional bladder neck obstruction.α1受体阻滞剂在女性功能性膀胱颈梗阻中的应用。
Urol Int. 2005;74(3):256-61. doi: 10.1159/000083559.
5
The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study.四个中心男性和女性下尿路症状的患病率。UrEpik研究。
BJU Int. 2003 Sep;92(4):409-14. doi: 10.1046/j.1464-410x.2003.04369.x.
6
Troublesome lower urinary tract symptoms in the community: a prevalence study.社区中令人困扰的下尿路症状:一项患病率研究。
Med J Aust. 1997 Jul 21;167(2):72-5. doi: 10.5694/j.1326-5377.1997.tb138783.x.